Literature DB >> 11181361

Antimicrobial susceptibility of Ehrlichia phagocytophila.

H W Horowitz1, T C Hsieh, M E Aguero-Rosenfeld, F Kalantarpour, I Chowdhury, G P Wormser, J M Wu.   

Abstract

Human granulocytic ehrlichiosis is a recently described disease caused by an obligate intracellular gram-negative organism recently named Ehrlichia phagocytophila. To expand our knowledge of the susceptibility of E. phagocytophila, we tested six New York State isolates for susceptibility to 12 antimicrobials using an HL-60 cell culture system. All of the isolates were susceptible to doxycycline (MIC, < or =0.125 microg/ml; minimum bactericidal concentration [MBC], 0.125 to 0.5 microg/ml), rifampin (MIC, < or =0.125 microg/ml; MBC, < or =0.125 microg/ml), ofloxacin (MIC, < or =2 microg/ml; MBC, < or =2 microg/ml), levofloxacin (MIC, < or =1 microg/ml; MBC, < or =1 microg/ml), and trovafloxacin (MIC, < or =0.032 microg/ml; MBC, < or =0.032 microg/ml). Isolates were uniformly resistant to amoxicillin, ceftriaxone, erythromycin, azithromycin, clarithromycin, and amikacin. For one strain, the MBC of chloramphenicol was < or =8 microg/ml. These data suggest that quinolone antibiotics and rifampin may be alternative agents for patients with intolerance to tetracyclines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181361      PMCID: PMC90374          DOI: 10.1128/AAC.45.3.786-788.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Human granulocytic ehrlichiosis in western Europe.

Authors:  A van Dobbenburgh; A P van Dam; E Fikrig
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

2.  Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle.

Authors:  S R Telford; J E Dawson; P Katavolos; C K Warner; C P Kolbert; D H Persing
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin.

Authors:  J S Bakken; P Goellner; M Van Etten; D Z Boyle; O L Swonger; S Mattson; J Krueth; R L Tilden; K Asanovich; J Walls; J S Dumler
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

4.  Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin.

Authors:  M I Buitrago; J W Ijdo; P Rinaudo; H Simon; J Copel; J Gadbaw; R Heimer; E Fikrig; F J Bia
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

5.  Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis.

Authors:  R B Nadelman; H W Horowitz; T C Hsieh; J M Wu; M E Aguero-Rosenfeld; I Schwartz; J Nowakowski; S Varde; G P Wormser
Journal:  N Engl J Med       Date:  1997-07-03       Impact factor: 91.245

6.  Human granulocytic ehrlichiosis: a case series from a medical center in New York State.

Authors:  M E Aguero-Rosenfeld; H W Horowitz; G P Wormser; D F McKenna; J Nowakowski; J Muñoz; J S Dumler
Journal:  Ann Intern Med       Date:  1996-12-01       Impact factor: 25.391

7.  Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins.

Authors:  M B Klein; C M Nelson; J L Goodman
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

8.  Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging?

Authors:  J S Bakken; J S Dumler; S M Chen; M R Eckman; L L Van Etta; D H Walker
Journal:  JAMA       Date:  1994-07-20       Impact factor: 56.272

9.  Direct cultivation of the causative agent of human granulocytic ehrlichiosis.

Authors:  J L Goodman; C Nelson; B Vitale; J E Madigan; J S Dumler; T J Kurtti; U G Munderloh
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

10.  Human granulocytic ehrlichiosis in Europe: clinical and laboratory findings for four patients from Slovenia.

Authors:  S Lotric-Furlan; M Petrovec; T A Zupanc; W L Nicholson; J W Sumner; J E Childs; F Strle
Journal:  Clin Infect Dis       Date:  1998-09       Impact factor: 9.079

  10 in total
  12 in total

1.  Anaplasma phagocytophilum infection in a domestic cat in Finland: Case report.

Authors:  Helka M Heikkilä; Anna Bondarenko; Andrea Mihalkov; Kurt Pfister; Thomas Spillmann
Journal:  Acta Vet Scand       Date:  2010-11-15       Impact factor: 1.695

Review 2.  Human granulocytic anaplasmosis.

Authors:  Johan S Bakken; J Stephen Dumler
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 3.  Coinfections acquired from ixodes ticks.

Authors:  Stephen J Swanson; David Neitzel; Kurt D Reed; Edward A Belongia
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  The prenylation inhibitor manumycin A reduces the viability of Anaplasma phagocytophilum.

Authors:  Qingming Xiong; Yasuko Rikihisa
Journal:  J Med Microbiol       Date:  2011-02-24       Impact factor: 2.472

5.  DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.

Authors:  M Maurin; C Abergel; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Wolbachia pipientis growth kinetics and susceptibilities to 13 antibiotics determined by immunofluorescence staining and real-time PCR.

Authors:  Florence Fenollar; Max Maurin; Didier Raoult
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Structure of the expression site reveals global diversity in MSP2 (P44) variants in Anaplasma phagocytophilum.

Authors:  Anthony F Barbet; Anna M Lundgren; A Rick Alleman; Snorre Stuen; Anneli Bjöersdorff; Richard N Brown; Niki L Drazenovich; Janet E Foley
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

8.  Antimicrobial susceptibility testing of two Lawsonia intracellularis isolates associated with proliferative hemorrhagic enteropathy and porcine intestinal adenomatosis in South Korea.

Authors:  Jung-Yong Yeh; Ji-Hye Lee; Hye-Ryun Yeh; Aeran Kim; Ji Youn Lee; Jeong-Min Hwang; Bo-Kyu Kang; Jong-Man Kim; In-Soo Choi; Joong-Bok Lee
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

9.  Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeensis, and Anaplasma phagocytophilum by real-time PCR.

Authors:  S Branger; J M Rolain; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

10.  Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States.

Authors:  Max Maurin; Johan S Bakken; J Stephen Dumler
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.